AU2019346585B2 - Polymorphic compounds and uses thereof - Google Patents

Polymorphic compounds and uses thereof Download PDF

Info

Publication number
AU2019346585B2
AU2019346585B2 AU2019346585A AU2019346585A AU2019346585B2 AU 2019346585 B2 AU2019346585 B2 AU 2019346585B2 AU 2019346585 A AU2019346585 A AU 2019346585A AU 2019346585 A AU2019346585 A AU 2019346585A AU 2019346585 B2 AU2019346585 B2 AU 2019346585B2
Authority
AU
Australia
Prior art keywords
compound
solid form
disease
peaks
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019346585A
Other languages
English (en)
Other versions
AU2019346585A1 (en
Inventor
Lisa Michelle Grove
David T. Jonaitis
Russell Birch Poe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astrocyte Pharmaceuticals Inc
Original Assignee
Astrocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrocyte Pharmaceuticals Inc filed Critical Astrocyte Pharmaceuticals Inc
Publication of AU2019346585A1 publication Critical patent/AU2019346585A1/en
Application granted granted Critical
Publication of AU2019346585B2 publication Critical patent/AU2019346585B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2019346585A 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof Active AU2019346585B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736979P 2018-09-26 2018-09-26
US62/736,979 2018-09-26
PCT/US2019/053076 WO2020069068A1 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Publications (2)

Publication Number Publication Date
AU2019346585A1 AU2019346585A1 (en) 2021-04-29
AU2019346585B2 true AU2019346585B2 (en) 2025-02-27

Family

ID=69885558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019346585A Active AU2019346585B2 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Country Status (12)

Country Link
US (2) US10765693B2 (https=)
EP (1) EP3856741A4 (https=)
JP (2) JP2022502405A (https=)
KR (1) KR20210093864A (https=)
CN (1) CN112930349A (https=)
AU (1) AU2019346585B2 (https=)
BR (1) BR112021005290A2 (https=)
CA (1) CA3113250A1 (https=)
EA (1) EA202190576A1 (https=)
IL (1) IL281718A (https=)
MX (1) MX2021003515A (https=)
WO (1) WO2020069068A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
IL276358B2 (en) 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
MX2023014655A (es) 2021-07-12 2024-01-12 Acadia Pharm Inc Formas cristalinas de trofinetida.
WO2023091791A1 (en) * 2021-11-22 2023-05-25 Astrocyte Pharmaceuticals, Inc. Methods of treating neurological and cardiovascular conditions
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
WO2019157317A1 (en) * 2018-02-09 2019-08-15 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7087589B2 (en) * 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
JP4012070B2 (ja) 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US7557092B2 (en) 2002-11-21 2009-07-07 University Of Utah Research Foundation Purinergic modulation of smell
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
WO2007139775A2 (en) 2006-05-23 2007-12-06 University Of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
US20100256086A1 (en) 2007-11-23 2010-10-07 Bar-Ilan Univetrsity Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2429565A4 (en) 2009-04-15 2012-11-14 Univ California NEURONIC OR NERVE PEPTIDES AND APTAMERS
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
ES2654363T3 (es) 2010-02-22 2018-02-13 University Of Connecticut Derivados de AMP para tratar enfermedades cardíacas
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
EA034135B9 (ru) 2013-03-13 2020-04-10 Тафтс Юниверсити Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
WO2015080940A1 (en) 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
EP3253388A4 (en) 2015-02-04 2018-11-21 Baker Heart and Diabetes Institute A method of treatment and compounds for use therein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
US20180021363A1 (en) * 2016-04-21 2018-01-25 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
WO2019157317A1 (en) * 2018-02-09 2019-08-15 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Balbach, S. et al., "Pharmaceutical evaluation of early development candidates "the 100 mg-approach", International Journal of Pharmaceutics. 2004, vol. 275, pages 1-12 *
Bastin, R. J. et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development. 2000, vol 4, 427-435 *
Caira, M. R., "Crystalline Polymorphism of Organic Compounds", Design of organic solids, Weber, E. et al "ED", Springer, 1998, pages 164-208 *
Singhal, D. et al., "Drug polymorphism and dosage form design: a practical perspective", Advanced Drug Delivery Reviews. 2004, vol. 56, pages 335-347 *

Also Published As

Publication number Publication date
IL281718A (en) 2021-05-31
KR20210093864A (ko) 2021-07-28
JP2024114885A (ja) 2024-08-23
US10765693B2 (en) 2020-09-08
WO2020069068A1 (en) 2020-04-02
WO2020069068A9 (en) 2020-05-14
EP3856741A1 (en) 2021-08-04
CN112930349A (zh) 2021-06-08
BR112021005290A2 (pt) 2021-06-22
NZ774215A (en) 2025-03-28
MX2021003515A (es) 2021-05-27
US20200093848A1 (en) 2020-03-26
EA202190576A1 (ru) 2021-09-03
US20210077518A1 (en) 2021-03-18
US11324769B2 (en) 2022-05-10
AU2019346585A1 (en) 2021-04-29
EP3856741A4 (en) 2022-06-22
CA3113250A1 (en) 2020-04-02
JP2022502405A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
AU2019346585B2 (en) Polymorphic compounds and uses thereof
CA3000483C (en) Compounds, compositions, and methods for modulating cftr
TWI516488B (zh) 嘧啶并［６，１－ａ］異喹啉－４－酮化合物之結晶型
CN109369524A (zh) 脯氨酰羟化酶抑制剂的晶体形态
CA3056426A1 (en) Quinolinyl compounds and their use as a kappa opioid receptor (kor) antagonists and products and methods related thereto
AU2019308940B2 (en) Crystal form of lanosterol prodrug compound and application thereof
EA026541B1 (ru) Дигидрат соединения бензотиофена, его применение и содержащая его фармацевтическая композиция
MX2015000783A (es) Antagonistas del receptor de 5-hidroxitriptamina 3 (5-ht3).
CN109071524A (zh) 作为eaat2活化剂的哒嗪衍生物
US20240368164A1 (en) Purine nucleosides, their intermediates, and methods of preparation thereof
EP3978478B1 (en) Tetrahydro-1h-benzazepine compound as potassium channel modulator, preparation method and use thereof
WO2025006827A1 (en) Substituted cyclic compounds and methods of treating phenylketonuria and other amino acidurias
EA046380B1 (ru) Полиморфные формы соединения a и их фармацевтические композиции
EP4178961A1 (en) Polymorphs of a gabaa alpha5 agonist and methods of using in the treatment of cognitive impairment
TW200526642A (en) Heterocyclic derivatives
EP4573081A1 (en) Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
WO2024144874A2 (en) Fast-dissolving dosage forms and uses thereof
HK40093043A (zh) GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
JP2021509398A (ja) 二重作用ｆｋｂｐ１２およびｆｋｂｐ５２阻害剤
HK40003887A (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241367A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365B (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241394A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)